We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM (FRONTIER)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05303467
Recruitment Status : Recruiting
First Posted : March 31, 2022
Last Update Posted : November 10, 2022
Sponsor:
Information provided by (Responsible Party):
Boston Scientific Corporation

Brief Summary:
The FRONTIER Study is a prospective, interventional, single-arm, multi-center, study to assess the safety and technical feasibility of TheraSphere GBM in patients with recurrent GBM.

Condition or disease Intervention/treatment Phase
Glioblastoma Multiforme Recurrent Glioblastoma Device: TheraSphere GBM Early Phase 1

Detailed Description:

Glioblastoma (GBM) is a highly aggressive brain cancer with a grave prognosis, resulting in <7% of patients surviving to five years post-diagnosis. External beam radiotherapy (EBRT) is currently a mainstay treatment for GBM; however, the dose delivered is limited by side effects. The targeted radiotherapy of the TheraSphere GBM Y-90 Glass Microsphere System (TheraSphere GBM) has promising potential to provide GBM patients with reduced side effects compared to external beam radiotherapy as well as a more effective treatment for this catastrophic disease.

The TheraSphere GBM device utilized in the FRONTIER trial is an yttrium-90 (Y-90) glass microsphere therapy for selective internal radiation therapy (endovascular radiotherapy) in recurrent GBM patients. The TheraSphere GBM treatment utilizes intra-arterial delivery and takes advantage of blood flow and direct tumor delivery. Treatment can be delivered by specific placement of a catheter close to the tumor through known angiographic techniques currently utilized by neuro-endovascular or interventional radiology physicians. Angiographic evaluation prior to treatment allows identification of tumor feeding arteries and definition of the treatment volume. TheraSphere GBM could achieve a high tumor response rate based on delivery of a tumor absorbed dose that is not currently possible with EBRT.

In consideration of the potential benefit of a more localized, targeted treatment with a reduced side effect profile compared to other treatment options, and the potential impact on patients' quality of life for this devastating disease, this First-in-Human Early Feasibility Study (EFS) of the TheraSphere GBM Y-90 Glass Microsphere System for the treatment of recurrent GBM is being conducted.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: The TheraSphere GBM Y-90 Glass Microsphere System (TheraSphere GBM) is an yttrium-90 (Y-90) glass microsphere therapy for selective internal radiation therapy (endovascular radiotherapy) in recurrent GBM patients
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: FRONTIER: A Feasibility Study to Evaluate the Safety of the TheRaSphere GliOblastoma (GBM) Device iN PaTIEnts With Recurrent GBM
Actual Study Start Date : July 30, 2022
Estimated Primary Completion Date : April 1, 2023
Estimated Study Completion Date : April 1, 2024

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Treatment
Absorbed dose target of 40 ± 10% Gy
Device: TheraSphere GBM
Single treatment of TheraSphere GBM device
Other Name: TheraSphere™ GBM Y-90 Glass Microspheres (TheraSphere GBM)




Primary Outcome Measures :
  1. The number of grade 3-5 non-hematological toxicities [ Time Frame: 30 days post index procedure ]
  2. The number of ≥ grade 3 CNS toxicities related to non-target embolization [ Time Frame: 30 days post index procedure ]
  3. Occurrence of symptomatic brain radiation necrosis requiring medical or surgical intervention and confirmed by pathology [ Time Frame: 30 days post index procedure ]
  4. The number of Grade 4 neutropenia events persisting for longer than 5 days [ Time Frame: 30 days post index procedure ]
  5. The number of grade 4 febrile neutropenia [ Time Frame: 30 days post index procedure ]
  6. The number of grade 4 thrombocytopenia or grade 3 thrombocytopenia with hemorrhage [ Time Frame: 30 days post index procedure ]

Secondary Outcome Measures :
  1. Rate of any treatment-related adverse events and treatment-related serious adverse events (not including predefined Limiting Toxicities) from first patient enrolled through study completion. [ Time Frame: Enrollment through 6 months post index procedure ]
  2. Change in post-treatment neurological function as assessed by the National Institute of Health Stroke Scale (NIHSS). [ Time Frame: Enrollment through 6 months post index procedure ]
    The NIHSS is a tool used by healthcare providers to objectively quantify the impairment caused by a stroke. The NIHSS is composed of 11 items, each of which scores a specific ability between a 0 and 4. For each item, a score of 0 typically indicates normal function in that specific ability, while a higher score is indicative of some level of impairment.

  3. Change in post-treatment neurological function as assessed by the modified Rankin Scale (mRS). [ Time Frame: Enrollment through 6 months post index procedure ]
    The mRS measures the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability on a scale from 0 (no symptoms at all) to 6 (death).

  4. Technical Success/Feasibility of TheraSphere GBM-- ability to deliver the target absorbed dose (+/- 20%) to the perfused volume for all patients treated with the device. Assessed from pre-screening through post-device delivery PET-CT/MRI. [ Time Frame: Pre-screening through post-device delivery PET-CT/MRI. ]
  5. Objective Response Rate* (ORR) from first patient enrolled through study completion [ Time Frame: Enrollment through 6 months post index procedure ]
  6. Progression Free Survival* (PFS) from first patient enrolled through study completion [ Time Frame: Enrollment through 6 months post index procedure ]
  7. Overall Survival (OS) from first patient enrolled through study completion [ Time Frame: Enrollment through 6 months post index procedure ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subject is 18 years or older and has signed and dated the trial informed consent form (ICF)
  2. Life expectancy ≥ 12 weeks
  3. Subject is willing and able to comply with the trial testing, procedures, and follow-up schedule
  4. History of a histologically confirmed diagnosis of glioblastoma per 2021 WHO criteria
  5. Have radiographic evidence of tumor progression/recurrence with measurable disease (≥ 1 cm to ≤ 5cm bidirectional diameters) by contrast-enhancement on MRI, according to RANO criteria
  6. Prior surgery and treatment with combination of radiotherapy and chemotherapy ± Tumor Treating Fields (Optune®)
  7. Prior cranial radiation dose < 66 Gy
  8. WHO performance status ≤ 2
  9. The interval since completion of cranial radiotherapy must be > 6 months, unless there is tissue confirmation of tumor recurrence/progression outside the previous radiation treatment field, in which case the interval since completion of cranial radiation must be at least 12 weeks
  10. Interval since last cytotoxic therapy until presumed date of intervention ≥ 1 cycle or ≥ 2 biological half-lives, i.e.

    1. ≥ 4 weeks since last dose of temozolomide
    2. ≥ 6 weeks since last dose of lomustine or other nitrosourea
    3. ≥ 2 weeks since last dose of a small molecule targeted agent
    4. ≥ 12 weeks from last dose of last bevacizumab infusion, Tyrosine Kinase Inhibitor, or other anti VEGFR therapy
  11. If receiving steroids, patient should be on a stable or decreasing dose equivalent to dexamethasone ≤ 6 mg/d, for at least 7 days prior to registration
  12. Have adequate organ and bone marrow function within 14 days prior to registration, as defined below:

    1. INR ≤ 1.2 (in absence of anticoagulation)
    2. Platelets ≥ 100,000/L
    3. Creatinine ≤1.5 mg/dL
    4. Absolute Neutrophil Count ≥1.5 x 109/L
    5. Hemoglobin ≥9.0 g/dL
  13. Have a negative pregnancy test within 14 days prior to registration on study (for FOCBP, female of child-bearing potential)
  14. Subject is a male or non-pregnant female. If female of child-bearing potential, and if sexually active must be using, or agree to use, a medically acceptable method of birth control as confirmed by the investigator
  15. Angiographic Mapping Inclusion Criteria:

    1. Accessible neurovascular anatomy that allows for safe microcatheter placement (single location) to infuse TheraSphere GBM to treat all of the T1 enhancing component of lesion confirmed by neuro-interventional team.
    2. Treatment volume is ≤ 150cc in the non-dominant hemisphere and non-eloquent regions as determined by multidisciplinary team. Eloquent regions should be defined as areas of the brain that maintain language, vision, sensory and motor function

Exclusion Criteria:

  1. Have bilateral gadolinium enhancing disease, tumor located in the posterior fossa, tumor involving critical subcortical structures (thalamus/hypothalamus, midbrain, brainstem, corticospinal tract, internal capsule, cerebral peduncle), tumor approximating or invading the brainstem and/or optic chiasma, leptomeningeal disease, or extracranial metastatic disease
  2. Have received more than 1 course of prior radiotherapy (EBRT)
  3. Have received radiosurgery, brachytherapy, or hypofractionated radiotherapy
  4. Have received more than 2 systemic treatment protocols (lines of treatment), not including maintenance temozolomide
  5. Have received more than 2 surgical GBM-related procedures
  6. Have received prior thoracic radiation therapy
  7. Are at increased risk of wound dehiscence by the discretion of the investigators (e.g. brain surgery within the last 3 months, poor skin condition, and/or previously infected surgical field or any other condition that is of increased infectious risk in the opinion of the neurosurgeon)
  8. Have uncontrolled epilepsy
  9. Have severe and/or insufficiently controlled intercurrent illness; patients with the following are not eligible:

    1. Hypertension grade 3 or higher without adequate control on medications
    2. Symptomatic or unstable cardiac disease, known to have right-to-left shunts, or severe pulmonary hypertension (pulmonary artery pressure > 90 mmHg)
    3. Pulmonary insufficiency (arterial oxygen pressure (Pa,O2) of < 60 mmHg, or oxygen saturation (Sa,O2) of < 90%) as measured by fingertip pulse oximeter
    4. Ongoing or active bacterial or viral infection requiring systemic treatment (including HIV)
    5. Pneumonitis
    6. Psychiatric illness/social situations that would limit compliance with study requirements
    7. Peripheral Neuropathy ≥ grade 1
    8. Any other illness or condition that the treating investigator feels would interfere with study compliance or would compromise the patient's safety, study endpoints or longevity
  10. Are currently pregnant or breast feeding (unless patient agrees to stop breastfeeding)
  11. Patients with a history of an active other malignancy within 1 year prior to registration. NOTE: Exceptions to this requirement include adequately treated non-melanoma skin cancer or lentigo maligna or carcinoma in situ without evidence of disease, or recurrent glioblastoma
  12. Patients with a history of ischemic cerebral disease and/or at risk of cerebral herniation
  13. Medical contraindication to undergo contrast-enhanced magnetic resonance imaging (MRI)
  14. Known history of hypersensitivity reactions to iodinated and/or gadolinium-based contrast
  15. Subject has received any other investigational agents within 4 weeks of treatment, or is currently participating, or plans to participate in, another

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05303467


Contacts
Layout table for location contacts
Contact: Sally Linda 763-494-1615 sally.linda@bsci.com
Contact: Franco Basarabescu 314-718-7289 franco.basarabescu@bsci.com

Locations
Layout table for location information
United States, California
University of California San Francisco Not yet recruiting
San Francisco, California, United States, 94143
Contact: Karishma Kumar    415-353-2653    Karishma.Kumar@ucsf.edu   
Principal Investigator: Nicholas Butowski, MD         
United States, Florida
Mayo Jacksonville Not yet recruiting
Jacksonville, Florida, United States, 32224
Contact: Ewa Szymkiewicz    855-776-0015    Szymkiewicz.Ewa@mayo.edu   
Principal Investigator: Alfredo Quinones-Hinojosa, MD         
United States, Illinois
Northwestern Univerity Recruiting
Chicago, Illinois, United States, 60611
Contact: Roger Stupp, MD    866-587-4322    roger.stupp@northwestern.edu   
Contact: Carlene Liana del Castillo    312-503-3209    carlene.castillo@northwestern.edu   
Principal Investigator: Samdeep Mouli, MD         
United States, Maryland
Johns Hopkins Interventional Radiology Center Not yet recruiting
Baltimore, Maryland, United States, 21287
Contact: Eugene Bosworth    443-974-8071    eboswor1@jhmi.edu   
Principal Investigator: Clifford Weiss, MD         
United States, New York
Lenox Hill Hospital Not yet recruiting
New York, New York, United States, 10075
Contact: Tamkia Wong    212-434-4836    twong4@northwell.edu   
Principal Investigator: John Boockvar, MD         
Sponsors and Collaborators
Boston Scientific Corporation
Layout table for additonal information
Responsible Party: Boston Scientific Corporation
ClinicalTrials.gov Identifier: NCT05303467    
Other Study ID Numbers: S2478
First Posted: March 31, 2022    Key Record Dates
Last Update Posted: November 10, 2022
Last Verified: November 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Glioblastoma
Recurrence
Disease Attributes
Pathologic Processes
Astrocytoma
Glioma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue